Abstract
To the Editor: The universal definition of myocardial infarction includes the increase and/or decrease in cardiac biomarkers, with at least 1 value greater than the 99th-percentile upper reference limit, concurrently with evidence of myocardial ischemia and corresponding clinical symptoms, electrocardiographic changes, or imaging evidence (1). Among cardiac biomarkers, cardiac troponins, including cardiac troponin I (cTnI)1 and cardiac troponin T (cTnT), have become the gold standard. Several noncardiac etiologies for increases in cardiac troponins have been described, however (2), and discordant values for cTnT and cTnI have been encountered in the clinical setting. The aim of our study was to systematically compare a cTnT assay and a cTnI assay with regard to discrepant values. This study was conducted in accord with the World Medical Association Declaration of Helsinki (3). We used the Architect cTnI STAT Troponin-I assay (Abbott Diagnostics) and the new high sensitive troponin T (hsTnT) assay (Troponin T hs) on the Modular Analytics system (Roche Diagnostics) to make 9004 simultaneous cTnI and cTnT measurements on 3995 patients and then analyzed the data. Because we were concerned about major discrepancies, we used 0.032 μg/L as the cutoff value for both the cTnI and hsTnT measurements. After applying this cutoff to our …
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.